Anthem Biosciences IPO: Date, Price, GMP & Review
Anthem Biosciences is gearing up for its highly anticipated ₹3,395 crore book-built IPO, and investors are buzzing with questions: “Is this IPO good or bad?”, “What’s the GMP today?”, and “When exactly does it open?”
Let’s dive into everything you need to know—broken into bite-sized sections, bullet points, and tables to keep it clear and actionable.
anthem biosciences ipo date
| Event | Date |
|---|---|
| Open for subscription | July 14, 2025 |
| Close for subscription | July 16, 2025 |
| Allotment finalized by | July 17, 2025 |
| Credit to Demat/Refunds | July 18, 2025 |
| Listing on BSE & NSE | July 21, 2025 |
anthem biosciences ipo price today
- Price band: ₹540–₹570 per share
- Face value: ₹2 per share
- Lot size: 26 shares (₹14,820 minimum investment)
- Employee discount: ₹50 per share
| Investor Category | Min Lots | Shares | Investment (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 26 | 14,820 |
| Retail (Max) | 13 | 338 | 193,260 |
| S-HNI (Min) | 14 | 364 | 207,480 |
| S-HNI (Max) | 67 | 1,742 | 9,93,000 |
| B-HNI (Min) | 68 | 1,768 | 10,07,760 |
anthem biosciences ipo gmp
The grey market premium (GMP) indicates investor sentiment before official listing. As of July 9, 2025:
A positive GMP suggests strong demand—good if you’re thinking of short-term gains, but remember GMP can swing quickly.
Also Read: Over 50 SEBI-Approved IPOs in 2025: Full Pipeline List
IPO DRHP & Review of Anthem Biosciences IPO
The RHP as well as the DRHP has brought to light the most important strengths and risks:
Strengths
- The services of CFPO (discovery to manufacturing) (end-to-end CRDMO services)
- The largest expanding capacity in specialized fermentation and synthesis in India
- Various sources of revenue: APIs, peptides, enzymes, biosimilars
- 196 ongoing initiatives; 600 strong professionals on the team
- International presence: 550+ customers in 44 countries
Risks
- Delays in approval of regulations
- Capacity underutilization
- Competition in the API markets
- Seasonal Revenue swings
- Data security & IP security trouble
anthem biosciences stock price & revenue
While Anthem isn’t yet listed, here’s what historical financials tell us:
| Metric | Value | Period |
|---|---|---|
| Revenue Growth (YoY) | 30% | FY 24 → 25 |
| PAT Growth (YoY) | 23% | FY 24 → 25 |
| EBITDA Margin | ~36.8% | FY 25 |
| ROE | 20.8% | - |
| ROCE | 26.9% | - |
| Debt/Equity | 0.05 | - |
Outlook
Healthy top-line acceleration and strong margins underscore operational excellence.
An excerpt of a biopharmaceutical firm that is listed like Anthem Biosciences IPO: good or bad?
Good when you want long-term exposure to the India CRDMO market, which shows high growth with diversified services.
Unfortunately, risk-averse investors should note: this is an offer for sale (OFS), so cash does not come to the company as cap-ex.
Key Takeaways
- Subscription Dates: July 14-16; Listing on July 21.
- Price & GMP: Price band is ₹540-₹570. The GMP of ₹67 indicates positive sentiment.
- Financials: Strong growth with 30% revenue and 23% profit increase, complemented by healthy margins.
- Action: Analyze based on your risk profile. The IPO presents fair fundamentals but faces potential market and regulatory headwinds.
